SYNTEX CLEANING VALIDATION PROCEDURES DRAW WARNING LETTER
SYNTEX CLEANING VALIDATION PROCEDURES DRAW WARNING LETTER from FDA May 6. An inspection of Syntex' Palo Alto, Calif. manufacturing facility in February and March "revealed serious deficiencies in the cleaning validation procedures for the solids, liquids, creams and ointments manufactured at the facility," FDA's San Francisco District Office told Syntex. "The inspection showed that both the cleaning validation studies completed in 1988 and the ongoing verification program are seriously flawed," the letter states.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth